JPMorgan Chase & Co. Has $73.10 Million Stock Holdings in Qiagen (NYSE:QGEN)

JPMorgan Chase & Co. grew its stake in shares of Qiagen (NYSE:QGEN) by 36.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,604,034 shares of the company’s stock after acquiring an additional 424,937 shares during the period. JPMorgan Chase & Co.’s holdings in Qiagen were worth $73,096,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of QGEN. GAMMA Investing LLC raised its position in Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after purchasing an additional 500 shares during the last quarter. Toronto Dominion Bank acquired a new stake in Qiagen during the 2nd quarter worth approximately $27,000. Massmutual Trust Co. FSB ADV grew its holdings in Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after acquiring an additional 243 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Qiagen during the third quarter valued at $53,000. Finally, Headlands Technologies LLC lifted its holdings in shares of Qiagen by 396.6% during the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after purchasing an additional 2,189 shares during the period. 70.00% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

QGEN has been the topic of several recent research reports. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a report on Thursday, October 17th. Jefferies Financial Group restated a “buy” rating and set a $54.00 price target (up previously from $42.00) on shares of Qiagen in a report on Tuesday, December 10th. Finally, Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Qiagen presently has an average rating of “Moderate Buy” and a consensus price target of $51.88.

Qiagen Stock Performance

Shares of QGEN stock opened at $44.97 on Friday. Qiagen has a 12 month low of $39.03 and a 12 month high of $47.44. The firm has a market capitalization of $10.26 billion, a PE ratio of 115.31, a price-to-earnings-growth ratio of 3.52 and a beta of 0.35. The firm has a fifty day simple moving average of $43.75 and a two-hundred day simple moving average of $43.82. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.